Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer

Patients with KRAS mutated colorectal cancer (CRC) represent a cohort with unmet medical needs, with limited options of FDA-approved therapies. Representing 40–45% of all CRC patients, they are considered ineligible to receive anti-EGFR monoclonal antibodies that have added a significant therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitra, Radhashree, Thavornwatanayong, Thongthai, Venkatesh, Madhu Kumar, Chandy, Carol, Vachss, Dov, Augustine, Titto, Guzik, Hillary, Koba, Wade, Liu, Qiang, Goel, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888417/
https://www.ncbi.nlm.nih.gov/pubmed/31766149
http://dx.doi.org/10.3390/ijms20225677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888417/
https://www.ncbi.nlm.nih.gov/pubmed/31766149
http://dx.doi.org/10.3390/ijms20225677

Ejemplares similares